Capex® Shampoo 0.01% is supplied as a shampoo formulation with a 12 mg fluocinolone acetonide capsule which is emptied into the shampoo base by the pharmacist at the time of dispensing. After mixing, Capex® Shampoo contains fluocinolone acetonide (6α, 9-Difluro-11β, 16α, 17,21 -tetrahydroxypregna-1,4-diene-3, 20-dione cyclic 16,17-acetal with acetone), a synthetic fluorinated corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as an anti-inflammatory and antipruritic agents. Chemically, Capex® Shampoo (fluocinolone acetonide topical shampoo) mixture is C24H30F2O8. It has the following structural formula: Fluocinolone acetonide in Capex® Shampoo (fluocinolone acetonide topical shampoo) has the molecular weight of 452.50. It is a white crystalline powder that is odorless, stable in light and melts at 270°F with decomposition; soluble in alcohol, acetone and methanol; slightly soluble in chloroform; insoluble in water. Each fluocinolone capsule contains 12 mg of fluocinolone acetonide, 548 mg of dibasic calcium phosphate dihydrate USP, and 240 mg of talc USP. The shampoo base contains aluminum acetate basic, benzalkonium chloride solution, boric acid, citric acid anhydrous, cocamido-ether-sulfate complex, cocoamine oxide, lauramide DEA, magnesium aluminum silicate, methylparaben, oat flour, propylene glycol, propylparaben, purified water, and fragrances, with D&C Yellow #10 and FD&C Blue #1 as coloring.

Source: http://www.rxlist.com

The following local adverse reactions have been reported infrequently with topical corticosteroids. They may occur more frequently with the use of occlusive dressings, especially with higher potency corticosteroids. These reactions are listed in an approximate decreasing order of occurrence: dryness, folliculitis, acneiform eruptions, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, miliaria, burning, itching, irritation, and hypopigmentation. Read the Capex Shampoo (fluocinolone acetonide topical shampoo) Side Effects Center for a complete guide to possible side effectsLearn More »

Source: http://www.rxlist.com

The pharmacist must empty the contents of the enclosed capsule into the shampoo base prior to dispensing to the patient. This product should be shaken well prior to use. No more than approximately one (1) ounce of the medicated shampoo should be applied to the scalp area once daily, worked into a lather, and allowed to remain on the scalp for approximately 5 minutes. The hair and scalp should then be rinsed thoroughly with water.

Source: http://www.rxlist.com

No information provided. Last reviewed on RxList: 5/8/2009
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

Capex® Shampoo (fluocinolone acetonide topical shampoo) is a low- to medium-potency corticosteroid indicated for the treatment of Seborrheic Dermatitis of the scalp. This product has not been proven to be effective in other corticosteroid-responsive dermatoses.

Source: http://www.rxlist.com

Capex® Shampoo (fluocinolone acetonide topical shampoo) is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. Last reviewed on RxList: 5/8/2009
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

Topically applied Capex® Shampoo (fluocinolone acetonide topical shampoo) can be absorbed in sufficient amounts to produce systemic effects (See PRECAUTIONS).

Source: http://www.rxlist.com

Capex® Shampoo (fluocinolone acetonide topical shampoo) is supplied as a two component package: a capsule which contains the active component fluocinolone acetonide 0.01%, and a separate package of liquid shampoo. The pharmacist must mix the content of the capsule into the base at the time of dispensing. Capex® Shampoo (fluocinolone acetonide topical shampoo) is dispensed to the patient in a 6 ounce bottle. Shake well before using. NDC 0299-5500-04 Store between 15° and 30° C (59° and 86° F) in tightly closed containers. Marketed by: Galderma Laboratories, L.P. Ft. Worth, Texas 76177 USA. Mfd. by: Hill Laboratories, Inc. Sanford, Florida 32773 USA. Revised: July 2000. Last reviewed on RxList: 5/8/2009
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

General Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticoid insufficiency after withdrawal of treatment. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment. Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. This may be done by using the ACTH stimulation, A.M. plasma cortisol, and urinary free cortisol tests. Patients receiving superpotent corticosteroids should not be treated for more than 2 weeks at a time and only small areas should be treated at any one time due to the increased risk of HPA suppression. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Infrequently, signs and symptoms of glucocorticoid insufficiency may occur requiring supplemental systemic corticosteroids. For information on systemic supplementation, see prescribing information for those products. Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios. (See PRECAUTIONS — Pediatric Use). If irritation develops, Capex® Shampoo (fluocinolone acetonide topical shampoo) should be discontinued and appropriate therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by a failure to heal rather than noting a clinical exacerbation as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing. If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of Capex® Shampoo (fluocinolone acetonide topical shampoo) should be discontinued until the infection has been adequately controlled. Laboratory Tests The following tests may be helpful in evaluating patients for HPA axis suppression.

• ACTH stimulation test
• A.M. plasma cortisol test
• Urinary free cortisol test

Carcinogenesis, mutagenesis, and impairment of fertility Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of Capex® Shampoo (fluocinolone acetonide topical shampoo) . Pregnancy Teratogenic effects: Pregnancy category C: Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women or teratogenic effects from Capex® Shampoo (fluocinolone acetonide topical shampoo) . Therefore, Capex® Shampoo (fluocinolone acetonide topical shampoo) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are secreted in human milk, caution should be exercised when Capex® Shampoo (fluocinolone acetonide topical shampoo) is administered to a nursing woman. Pediatric Use Safety and effectiveness in children and infants have not been established. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression when they are treated with topical corticosteroids. They are therefore also at a greater risk of glucocorticoid insufficiency after withdrawal of treatment and of Cushing's syndrome while on treatment. Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children. HPA axis suppression, Cushing's syndrome and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches and bilateral papilledema. Last reviewed on RxList: 5/8/2009
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com